Illumina Inc. Blows Past Guidance in Second Quarter With Strong NovaSeq Demand

Illumina Inc. (NASDAQ: ILMN) started out 2017 on a positive note by beating its first-quarter revenue guidance and coming in at the upper end of its earnings guidance. However, there were a few negatives in those results, including lower gross profit.

The gene-sequencing company announced its second-quarter results after the market closed on Tuesday. There were even more positives this time around. Here are the highlights from Illumina's quarterly update.

Image source: Getty Images.

Source: Fool.com

Illumina Inc. Aktie

Illumina Inc. muss heute herbe Verluste wegstecken. Die Aktie notiert im Vergleich zu gestern um -5,59 % tiefer.
Die Community bevorzugt Illumina Inc., mit deutlich mehr Buy- (27) als Sell-Einschätzungen (4).
Ein Kursziel von 162 € für Illumina Inc. würde eine Steigerung von mehr als 50% gegenüber dem aktuellen Kurs von 107.86 € bedeuten.

Like: 0

ILMN

Teilen